Fed. Circ. Won't Rethink Axed Stanford Kidney Test Patents
The Federal Circuit on Friday declined to review en banc a panel's decision that three Stanford University diagnostic patents licensed to a developer of commercial tests for kidney transplant rejections are ineligible for...To view the full article, register now.
Already a subscriber? Click here to view full article